Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Size

Report ID: GMI5864
Published Date: May 2023
Report Format: PDF

Download Free Sample

GLP-1 Receptor Agonist Market Size

GLP-1 Receptor Agonist Market size was evaluated to be around USD 22.4 billion in 2022 and is anticipated to exhibit sustainable growth at a CAGR of around 9.6% during the forecast period, i.e., from 2023 to 2032. The growth is attributed primarily to factors such increasing prevalence of chronic diseases such as diabetes and obesity, increasing R&D activities for developing novel therapeutics, advancement in formulation of oral GLP-1 receptor agonist, and increasing awareness about diagnosis and treatment option for diabetes.

To get key market trends

Download Free Sample

Glucagon-like peptide-1 (GLP-1) receptor agonists bind and activate the GLP-1 receptor, stimulating glucose-dependent insulin release from the pancreatic islets and slowing gastric emptying. GLP-1 is an important gut-derived hormone that enhances insulin secretion. In the presence of elevated glucose, it increases glucose-dependent insulin synthesis and the in vivo secretion of insulin from pancreatic beta cells. In addition to this, GLP-1 suppresses glucagon secretion, reduces food intake via the reduction of appetite, and promotes beta cell proliferation.

GLP-1 Receptor Agonist Market Report Attributes
Report Attribute	Details
Base Year:	2022
GLP-1 Receptor Agonist Market Size in 2022:	USD 22.4 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	9.6%
2032 Value Projection:	USD 55.8 Billion
Historical Data for:	2018 to 2022
No. of Pages:	160
Tables, Charts & Figures:	280
Segments covered:	Drug class, Route of administration, Application, Distribution channel, and Region
Growth Drivers:	Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Increasing awareness about diagnosis and treatment options for diabetes
Pitfalls & Challenges:	Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players

Learn more about the key segments shaping this market

Download Free Sample

GLP-1 receptor agonists are one of the antidiabetics and are suitable initial therapy for patients with type 2 diabetes and those who are at high risk of cardiovascular diseases. In addition to these, it can be used as an initial therapy for high-risk heart failure or chronic kidney disease. GLP-1 receptor agonist therapies facilitate restoring insulin secretory functions, improving glycemic control, and reducing weight in type 2 diabetes patients.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for GLP-1 receptor agonist was around USD 22.4 billion in 2022 and will exhibit sustainable growth at around 9.6% CAGR from 2023 to 2032.

Global GLP-1 receptor agonist industry from the type 2 diabetes mellitus segment accounted for the largest share in 2022 as they play a vital role in stimulating the release of insulin and suppressing glucagon secretion when the blood glucose levels are high.

North America held the highest revenue share GLP-1 receptor agonist market in 2022, owing to a high prevalence of chronic diseases such as diabetes and obesity, and increasing investments for R&D for developing new drugs for treating diabetes and obesity.

Eli Lilly and Company, Sanofi, Pfizer.Inc, Amgen, Inc., Novo-Nordisk A/S, AstraZeneca, Innovent Biologics, Inc., Sun Pharmaceutical Industries Ltd., PegBio Co., Ltd., and Boehringer Ingelheim International GmbH.